Gluten Intolerance Treatment Market Size & Share, by Drug Type (Antihistamines, Epinephrine); Gluten-Related Disorders (Celiac Disease, Dermatitis Herpetiformis, Gluten Ataxia, Wheat Allergy, Non-Celiac Gluten Sensitivity); Pharmacy Distribution Channel (Hospital, Retail, Specialty, Online) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 5081
  • Published Date: Jun 28, 2023
  • Report Format: PDF, PPT

Companies Dominating the Gluten Intolerance Treatment Landscape

top-features-companies
    • Takeda Pharmaceutical Company Limited
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • ActoBio Therapeutics, Inc.
    • Precigen, Inc.
    • Calypso Biotech BV
    • ImmunogenX, Inc.
    • Alvine Pharmaceuticals
    • Dr. Falk Pharma GmbH
    • ImmusanT, Inc.
    • Zedira GmbH
    • FunZyme BioTechnologies S.A.
    • Amyra Biotech AG

Browse Key Market Insights with Data Illustration:

In-the-news

In The News

  • ActoBio Therapeutics, Inc., a wholly-owned subsidiary of Intrexon Corporation announced that the U.S. Food and Drug Administration (FDA) has given its permission to an Investigational New Drug (IND) application for AG017. It is an innovative orally-delivered therapeutic candidate for the treatment of celiac disease.
  • Takeda Pharmaceutical Company Limited, Zedira GmbH and Dr. Falk Pharma GmbH announced a collaboration and licensing agreement to develop ZED1227/TAK-227. TAK-227 is a Phase 2b investigational therapy for the treatment of celiac disease designed to prevent the immune response to gluten in celiac disease, a serious autoimmune disease where the ingestion of gluten leads to inflammation and damage to the small intestine.

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 5081
  • Published Date: Jun 28, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The growing prevalence of autoimmune, allergic, and non-autoimmune-allergic GRDs and the rising damage of gut flora are the major factors driving the growth of the gluten intolerance treatment market.

The market of gluten intolerance treatment is anticipated to attain a CAGR of ~14% over the forecast period, i.e., 2023 – 2035.

The major players in the market are Precigen, Inc., ImmunogenX, Inc., Calypso Biotech BV, Zedira GmbH, and FunZyme BioTechnologies S.A.

The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by type. gluten-related disorders, distribution channel, and region.

The celiac disease segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.

Challenges in diagnoses are estimated to be the growth hindering factors for the market expansion.

The market in the Europe region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying